UNIVERSITY OF BIRMINGHAM
University of Birmingham Research at Birmingham

A multi-targeting pre-clinical candidate against drug-resistant tuberculosis

Kaur, Parvinder; Potluri, Vijay; Ahuja, Vijay Kamal; Naveenkumar, C N; Krishnamurthy, Ramya Vadageri; Gangadharaiah, Shruthi Thimmalapura; Shivarudraiah, Prasad; Eswaran, Sumesh; Nirmal, Christy Rosaline; Mahizhaveni, Balasubramanian; Dusthackeer, Azger; Mondal, Rajesh; Batt, Sarah M; Richardson, Emily J; Loman, Nicholas J; Besra, Gurdyal Singh; Shandil, Radha Krishan; Narayanan, Shridhar

DOI:
10.1016/j.tube.2021.102104

License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version
Peer reviewed version

Citation for published version (Harvard):
Kaur, P, Potluri, V, Ahuja, VK, Naveenkumar, CN, Krishnamurthy, RV, Gangadharaiah, ST, Shivarudraiah, P, Eswaran, S, Nirmal, CR, Mahizhaveni, B, Dusthackeer, A, Mondal, R, Batt, SM, Richardson, EJ, Loman, NJ, Besra, GS, Shandil, RK & Narayanan, S 2021, 'A multi-targeting pre-clinical candidate against drug-resistant tuberculosis', *Tuberculosis*, vol. 129, 102104. https://doi.org/10.1016/j.tube.2021.102104

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.
•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
•User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 25. Apr. 2024

A Multi-Targeting Pre-Clinical Candidate against Drug-Resistant Tuberculosis

*Parvinder Kaur[a], Vijay Potluri[a], Vijay Kamal Ahuja[a], C.N.Naveenkumar[a], Ramya Vadageri Krishnamurthy[a]. Shruthi Thimmalapura Gangadharaiah[b], Prasad Shivarudraiah[b], Sumesh Eswaran[b], Christy Rosaline Nirmal[c], Balasubramanian Mahizhaveni[c], Azger Dusthackeer[c], Rajesh Mondal[c], Sarah M. Batt[d], Emily J. Richardson[d], Nicholas J. Loman[d], Gurdyal Singh Besra[d], Radha Krishan Shandil[a], Shridhar Narayanan[a].

[a]Foundation for Neglected Disease Research, Bangalore, India.

[b]Anthem BioSciences. Pvt. Ltd., No 49, Canara Bank Road, Hosur Rd, Electronics City Phase 1, Bommasandra Industrial Area, Bengaluru, Karnataka 560099, India.

[c]National Institute for Research in Tuberculosis, No.1, Mayor Sathiyamoorthy St, Chetpet, Chennai, Tamil Nadu 600031, India.

[d]Insitiute of Microbiology & Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

*parvinder.kaur@fndr.in. Foundation for Neglected Diseases Research (FNDR), Plot 20A, KIADB Industrial Area, Veerapura, Doddaballapur, Bangalore – 561203, Karnataka, India.

Abstract

FNDR-20081 [4-{4-[5-(4-Isopropyl-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-piperazin-1-yl}-7-pyridin-3-yl-quinoline] is a novel, first in class anti-tubercular pre-clinical candidate against sensitive and drug-resistant *Mycobacterium tuberculosis* (Mtb). *In-vitro* combination studies of FNDR-20081 with first- and second-line drugs exhibited no antagonism, suggesting its compatibility for developing new combination-regimens. FNDR-20081, which is non-toxic with no CYP3A4 liability, demonstrated exposure-dependent killing of replicating-Mtb, as well as the non-replicating-Mtb, and efficacy in a mouse model of infection. Whole genome sequencing (WGS) of FNDR-20081 resistant mutants revealed the identification of pleotropic targets: *marR* (Rv0678), a regulator of MmpL5, a transporter/efflux pump mechanism for drug resistance; and Rv3683, a putative metalloprotease potentially involved in peptidoglycan biosynthesis. In summary, FNDR-20081 is a promising first in class compound with the potential to form a new combination regimen for MDR-TB treatment.

Keywords

Drug resistance, *Mycobacterium tuberculosis*, first-in-class, multi-target, pre-clinical candidate.

51 **Introduction**

52 Tuberculosis (TB) caused by *Mycobacterium tuberculosis* is a communicable disease that is a major
53 cause of ill health, one of the top 10 causes of death worldwide and the leading cause of death from a
54 single infectious agent (ranking above HIV/AIDS) [1]. Despite notable progress to control TB, in 2019,
55 globally an estimated 10 million people developed TB, 1.4 million died and about 0.4 million of these
56 cases were due to HIV co-infection [1]. Furthermore, the TB drug-resistance is increasing globally and
57 has limited treatment options [1]. There are approximately 206 030 reported cases [1] representing multi-
58 drug resistant TB (MDR/RR-TB) in 2019, with most cases attributed geographically to India (24%);
59 China (13%) and the Russian Federation (10%). Additionally, 5.99% of cases were reported as
60 extensively drug-resistant TB (XDR-TB). The 'End TB Strategy' aims to reducing TB deaths and
61 incidence by 2025 [2]. But the global incidence and mortality rates have fallen by a mere 2- 3% each
62 year. Hence, to achieve these targets, we need novel bactericidal anti-TB drugs, efficacious against
63 replicating and, non-replicating populations, as well as against drug resistant TB [1,3,4].

64 About a quarter of the global population is latently infected with *Mycobacterium tuberculosis* (Mtb),
65 and prone to develop active TB disease during their lifetime if immunocompromised [1]. Thus, latent-
66 TB can seriously skew the treatment logistics and strategies. Hence, novel compounds with activity
67 against non-replicating populations (NRP) of Mtb must be developed as a priority. Few new anti-TB
68 drugs have reached the stage of clinical development and use in patients after a gap of 50 years
69 (Bedaquiline, Delamanid, Pretomanid (PA824)), while a few more are in the pipeline e.g.Q203, TBA-
70 7371 etc. [5,6]. These compounds offer hope that new drugs hitting novel targets in Mtb could be
71 successfully developed for the treatment of TB.

72 The discovery of new chemical scaffolds with novel mechanism of action, are necessary to develop
73 improved therapeutic combinations for the treatment of MDR-TB. We synthesized and screened [7] a
74 small molecule library of quinoline derivatives (Figure 1) and identified a potent inhibitor FNDR-20081
75 [8], against *M. tuberculosis* H37Rv with an MIC of 0.5-2 µg/mL. FNDR-20081 is a 1st in class novel
76 drug-like molecule, highly TB-specific, non-cytotoxic (IC_{50} >100µM) on THP-1 and HepG2 cells.
77 FNDR-20081 is active *in-vitro* against sensitive and MDR TB clinical isolates, exhibited no adverse
78 drug-drug interactions with first- and second-line anti-TB drugs *in-vitro*, orally bioavailable and showed
79 *in-vivo* efficacy. FNDR-20081 represents a potential anti-tubercular candidate to develop novel

combinations with existing drugs and new compounds that may become clinically relevant in the treatment of MDR TB.

101 **Materials and methods**

102 **Drugs, Chemicals and Media used:** Reference antibiotics Streptomycin (STR), Isoniazid (INH),
103 Rifampicin (RIF), Ethambutol (EMB), Amikacin (AMK), Capreomycin (CAP), Kanamycin (KAN), D-
104 cycloserine (DCS), Clofazimine (CLO) and Fluoroquinolones (FQs) were obtained from Sigma-Aldrich
105 (Merck USA). Media and the supplements used in this study were Middlebrook 7H11 Agar base,
106 Middlebrook 7H9 broth base and ADC (albumin, dextrose, and catalase) supplements (BD/Difco),
107 Tween-80 (Merck-SIGMA). The stock solutions (12.8 mg/mL) of test compounds and the reference
108 drug controls (e.g., RIF) were prepared separately in dimethyl sulfoxide (DMSO) or in Milli-Q water
109 (e.g., INH) as appropriate. Working solutions were freshly prepared at the time of experiment.

110 **Bacterial strains:** *M. tuberculosis* H37Rv (WT) and a total of 61 different reference strains (ATCC),
111 and clinical isolates (National Institute for Research in Tuberculosis, NIRT Chennai) of Mtb, as well as
112 *Mycobacterium bovis (M. bovis)* BCG Pasteur strains (University of Birmingham) were used in this
113 study. Mtb cultures were sub-cultured and grown in Middlebrook 7H9 broth supplemented with 10%
114 (v/v) Middlebrook ADC, 0.05% (v/v) Tween-80 and 0.25% (v/v) glycerol) to a cell density of 10^9
115 colony-forming units (CFU)/mL. Glycerol stocks were prepared and stored at -80°C in 0.5ml aliquots.
116 A single vial was thawed and used each time for each experiment. Apart from Mtb, the compounds were
117 profiled against another bacterial non-TB panel or ESKAPE panel (*Enterococcus faecium* [VRE],
118 *Staphylococcus aureus* [MRSA], *Klebsiella pneumoniae* [sensitive], *Acinetobacter baumannii*
119 [sensitive], *Pseudomonas aeruginosa* [sensitive], *Enterobacter aerogenes* [sensitive]) as well. This
120 study was approved by the institutional bio-safety committee (IBSC).

121 **MIC determination in *M. tuberculosis* WT and *M. bovis* BCG, as well as clinical isolates:** Minimum
122 inhibitory concentrations (MICs) were determined against Mtb strains by the standard broth dilution
123 method according to CLSI guidelines M24 [9,10,11]. Briefly, the test compounds were dissolved in
124 DMSO, serially diluted by 2-fold in a 10-concentration dose response (10c-DR) ranging from 128 to
125 0.25 µg/mL in 96-well plates. Middlebrook 7H9 broth (supplemented with 10% ADC) complete media
126 was used for the assay. Mtb culture was added as 200µL in each well to all columns except the media
127 control column (200µl of media was added) to give a final inoculum of 3-7x10^5 cfu/mL. The quality
128 control (QC) included: media controls, growth controls (including DMSO controls), and the reference
129 drug inhibitors (Rifampicin and Isoniazid). The assay plates were incubated at 37°C, resazurin dye was
130 added on 6th day, and the results were noted on the 7th day as colorimetric readout. The blue wells

131 indicated inhibition of growth, while the pink wells indicated uninhibited growth. The MIC was defined
132 as the minimum concentration that completely inhibited the growth of bacteria. MIC assays were carried
133 out in duplicate.

134 The MIC values of FNDR-20081 for a total of 61 Mtb clinical isolates were evaluated. These clinical
135 isolates comprised of XDR (5), MDR (33), SDR (15), drug-sensitive (8) Mtb strains. The definition of
136 SDR, MDR, and XDR is as follows: SDR= Resistance to any single drug (INH, RIF, STR, EMB, PAS,
137 AMK, KAN, CAP, OFX, MXF) MDR=Resistance to any 2 or more drugs of the above mentioned,
138 XDR= Resistance to all 1st line drugs + 2nd line+ 1 injectable drug.

139 *M. bovis* BCG Pasteur strain was cultured statically at 37˚C, 5% CO_2 in liquid media (Middlebrook 7H9,
140 Difco, supplemented with 10% (v/v) Middlebrook ADC, 0.05% (v/v) Tween-80 and 0.25% (v/v)
141 glycerol) or solid media (Middlebrook 7H11 agar, Difco, with 0.5% (v/v) glycerol and 10% (v/v)
142 Middlebrook OADC). The MIC of FNDR-20081 for *M. bovis* BCG, on solid media, was determined
143 by plating out 10 µL spots of 10^4, 10^3, 10^2 and 10^1 cells onto 5 mL 7H11 agar plates of a series of 2-fold
144 dilutions of the compound. The MIC was defined as the lowest concentration of FNDR-20081 that
145 prevented any growth of the bacterium.

146 **Determination of minimum bactericidal concentration (MBC):** MBC was determined by a
147 procedure reported previously [8]. Serial 2-fold dilutions of test molecule up to 6-fold of its MIC (0.25
148 to 32 µg/mL) and INH (0.039-2.5 µg/mL) were prepared in DMSO and water respectively in a 96-well
149 microtiter plate. A drug-free control was also included in the tests. All wells were inoculated with 200µl
150 bacterial inoculum from the frozen enumerated stock of Mtb to give a final cell density of 1×10^5
151 CFU/mL in each well. The microtitre plate was incubated at 37°C for 7 days. MBC was determined by
152 serial 10-fold dilution of these tubes using 7H9 broth or phosphate buffered saline (0.1 M, pH 7.4) as a
153 diluent. Each dilution (0.5 mL) was plated in triplicate onto Middlebrook 7H10 agar supplemented with
154 10% OADC and incubated at 37°C. The plates were counted for CFU on day 21 and day 28 of
155 incubation. MBC was taken as the lowest concentration that killed 99% of the initial Mtb inoculum [11].

156 **Drug Combination MIC assay:** The *in vitro* drug interaction study was performed as described
157 previously [12]. Briefly, synergistic/additive/antagonist interactions of test molecule with known anti-
158 TB drugs against *M. tuberculosis* H37Rv (INH, RIF, EMB, AMK, CAP, STR, OFX and MXF, as well
159 as the new drugs in the pipeline: Bedaquiline BDQ, Pretomanid/PA-824, and Linezolid LZD), were

160 evaluated by determining the MICs of the test molecule, anti-TB drugs alone and in combinations in 96-
161 well plates by checkerboard method. Each combination was prepared so the mid-point concentration of
162 each molecule equaled its MIC to capture synergism as well as antagonism if any (i.e., both the drugs
163 were centering at their MIC). Serial dilutions were made in subsequent wells. Mtb culture was added as
164 200µl in each well to give a bacterial density of approximately $3\text{-}8\times10^5$ CFU/mL in each well. The plates
165 were packed and incubated at 37°C for the next 6 days. The dye (Resazurin) was added on 6th day and
166 the incubation was continued; the results were read by visual colorimetric inspection. MICs of each drug
167 alone and in combination were described where the lowest concentrations showing no visible color
168 change from blue to pink (i.e., no growth of *M. tuberculosis*) were considered minimum inhibitory
169 concentrations. The combinatorial reductions in MICs were used to calculate the fractional inhibitory
170 concentration (FIC). Fractional inhibitory concentration indices (FICI) were interpreted as follows: ≤0.5,
171 synergism; >0.5-4.0, additive or indifference; and >4.0, antagonism.

172 **MIC determination in the presence of serum/albumin to determine protein binding:** MIC
173 determination in the presence of serum/albumin was performed to evaluate the effect of protein binding,
174 if any. This assay was performed by using a previously described broth microdilution assay, with minor
175 modifications [13]. The MICs against *M. tuberculosis* H37Rv were determined under three different
176 conditions: 1). without protein enrichment, 2). in the presence of 10% bovine serum albumin (BSA),
177 and 3). in 10% fetal bovine serum (FBS).

178 **Mycobactericidal activity of FNDR-20081 on replicating Mtb to determine killing kinetics:** The
179 killing kinetics assay on replicating Mtb population was performed as described previously [13,14,15].
180 The Mtb (H37Rv) culture was inoculated at ~3-8 X 10^7cfu/mL in fresh Middlebrook 7H9 complete
181 medium containing varying concentrations of FNDR-20081 (0.015-256 µg/mL). The cultures were
182 incubated at 37ºC for different time points and enumerated, respectively. For the CFU enumeration,
183 aliquots from the cultures containing different concentrations of the compounds were collected at day-
184 3, day-7 and day-14 and plated at various dilutions (10^{-1} to 10^{-8}) to get countable colonies. Rifampicin
185 was used as the assay quality control. Data was analysed and plotted as $\log_{10}$ cfu/mL at day-3, day-7,
186 and day-14 as a function of concentration of FNDR-20081 to calculate the range of concentration that
187 shows killing potential.

188 **Mycobactericidal activity of FNDR-20081 on non-replicating Mtb:** FNDR-20081 was screened
189 against non-replicating Mtb in three different models of the various simulated conditions [11,16], to test

190 its ability to kill various dormant populations of Mtb under: 1) low pH, 2) nutritional starvation and 3)
191 stationary phase conditions. 1) Low pH model: Mtb was adapted to low pH condition by allowing it to
192 grow under a pH of 6.0±0.1 at 37°C for 4 weeks in the Middlebrook 7H9 complete medium containing
193 KH_2PO_4, casein hydrolysate, glycerol. Low pH adapted Mtb inoculum was sub-cultured into previously
194 described freshly made low pH media containing various concentrations (256 to 0.5µg/mL) of the
195 FNDR-20081. PZA was used as a positive control for this assay. 2) Nutrient starvation model: the Mtb
196 culture was pelleted, washed 2 times with phosphate-buffered saline (PBS) and reconstituted in PBS to
197 remove all the nutrients from the media. This was followed by incubation at 37°C for 6 weeks to starve
198 or nutritionally deprive the culture of Mtb. Starved cultures were exposed to various concentrations (256
199 to 0.5µg/mL) of the compound. RIF was used as a positive control in this assay. 3) Stationary phase
200 model: Mtb culture inoculated in Middlebrook 7H9 complete medium was incubated at 37°C/ 6 months
201 (to achieve stationary growth phase of Mtb) and was used for stationary phase model. A 6-month-old
202 Mtb culture was diluted appropriately (~10^7cfu/mL) in the spent medium and exposed to various
203 concentrations (1-256 µg/mL) of the compound. Rifampicin was used as a positive control for this assay.

204 The assay plates for the respective models were incubated at 37°C for 21 days. After 21-days, the
205 respective exposed cultures were appropriately diluted (10^{-1} to 10^{-8}) and plated to get countable colonies
206 as colony forming units (cfu) for enumeration of the survivors of compound exposed vs. the un-exposed
207 controls. The data was analysed and plotted using GraphPad Prizm v5.0.

208 **Cytotoxicity:** Cytotoxicity of the compound was tested on HepG2, and phorbol 12-myristate 13-acetate
209 (PMA) -activated THP-1 macrophage cell lines [12]. The compound was added at 2-fold concentrations
210 (64-0.125µg/mL) to the respective cell lines. The plates were incubated at 37°C/5% CO_2 for 48 hrs. The
211 colorimetric readings were taken after the addition of resazurin dye [12].

212 **Intracellular efficacy of FNDR-20081:** To test drug efficacy against slow or non-replicating bacilli in
213 the intracellular compartment, tumor macrophage-derived cell line THP-1 was used. The THP-1 cells
214 were grown in RPMI medium (Gibco-BRL Life Technologies, Gaithersburg, Md.) in 75-cm^2 flasks
215 (*Corning Costar Corp., Cambridge, Mass*.).

216 RPMI complete media (100 mM sodium pyruvate, 200 mM L-glutamine, 3.7 g of sodium bicarbonate
217 per liter (*SIGMA*), and 10% fetal bovine serum (*Gibco-BRL Life Technologies*)) was used without any
218 antibiotics. The macrophages were counted in a hemocytometer, viability was determined by trypan

219 blue exclusion, and the macrophages were seeded in 24-well plates (Nunc, Roskilde, Denmark) with
220 complete RPMI at a density of approximately 5×10^5 cells/well and incubated overnight. The THP-1
221 cells were differentiated by 50nM phorbol 12-myristate 13-acetate (PMA) induction to achieve
222 macrophage phenotypes and were incubated at 37°C/48-72h/5% CO_2. After 48 h of activation, the THP-
223 1 macrophages were infected with *M. tuberculosis* H37Rv at a multiplicity of infection (MOI) of 1:10
224 [12] and were incubated for 2 h at 37°C / 5% CO_2. The medium containing the mycobacteria was
225 discarded, macrophage monolayers were washed twice with 3 mL of PBS ($+Ca^{2+} + Mg^{2+}$) to remove the
226 free bacteria and replenished with fresh complete RPMI. Sets of triplicate wells were lysed (0.05% SDS)
227 at specific time-points and enumerated to estimate the numbers of intracellular Mtb 2hr post-infection
228 [13,14,15]. The phosphate-buffered saline washed monolayers were lysed by adding 1 mL of water plus
229 0.05% sodium dodecyl sulfate (SDS) for 5 min. The lysate was serially diluted and plated onto
230 Middlebrook 7H11 agar plates (Difco Labs) for cfu enumeration (read after 3 to 4 weeks).

231 For the remaining wells, at 2 h post-infection the test compound (FNDR-20081) was added to sets of
232 triplicate wells at respective concentrations (64-4-1 µg/mL) as well as the assay control RIF (16-4-1
233 µg/mL). The final concentration of DMSO in the medium was maintained at 1% for all conditions. Sets
234 of replicates from the infection control, test and the reference wells with each drug concentrations were
235 sampled on 0, 3, 5, and 7 days. The wells were washed to remove the extracellular bacteria, if any,
236 released after lysis of macrophages. The cell lysates were serially diluted and plated onto Middlebrook
237 7H11 agar plates to estimate the numbers of intracellular viable mycobacteria. The intracellular
238 mycobacterial killing rates of rifampin were generated by plotting the $\log_{10}$ cfu/mL against the
239 broth/MIC ratio and the AUC/MIC ratio.

240 **FNDR-20081 activity under different media conditions:** The in vitro growth inhibition of FNDR-
241 20081 was tested on Mtb H37Rv growing under different media conditions, as per CLSI with
242 modifications in media supplements respectively to mimic the protein-rich and lipid-rich host
243 conditions. The activity was monitored in the presence of casitone, BSA, cholesterol, tyloxapol and Di-
244 palmitoyl-phosphatidyl-choline (DPPC). The respectively adapted Mtb cultures were exposed to
245 different concentrations of 2-fold diluted compound (256-0.5 µg/mL). The assay plates were incubated
246 at 37°C for 14-days. The results were noted by visual turbidity.

247 **Activity against ESKAPE pathogens:** FNDR-20081 was tested against a panel of ESKAPE organisms
248 to test its activity against Gram-positive and Gram-negative pathogens. The assay plates were incubated

249 for 24 hrs at 37°C. At the end of the assay visual turbidometric readings were taken and the results were
250 noted [7,9,12].

251 **Generation of *Mycobacterium bovis* (*M. bovis*) BCG Spontaneous Resistance Mutants to FNDR-
252 20081:** Target identification studies were performed through spontaneous mutant generation and whole
253 genome sequencing (WGS). Over-expression studies were also used to confirm new targets identified
254 by WGS of spontaneous resistant mutants.

255 To generate spontaneous mutants resistant to FNDR-20081, 10^8 cfu of log phase cells (OD_{600} of 0.8-1.0)
256 were plated out onto 7H11 agar containing 5×, 10× and 20× MIC of the compound. To confirm
257 resistance, putative mutants were grown in liquid 7H9 media, in the absence of the compound, to log
258 phase. The cells were spotted as 10 µL of 10^4, 10^3, 10^2 and 10^1 cfu on to 7H11 agar containing 5× MIC
259 of FNDR-20081. Resistant mutants that grew on this plate were subjected to whole-genome sequencing
260 (WGS) to determine mutations conferring resistance. Cells were grown to log phase in 50 mL liquid
261 media, containing 3× MIC of FNDR-20081, and the genome purified. WGS and the alignment to the
262 reference genome of *M. bovis* BCG Pasteur 1173P2 (accession number: NC_008768.1) was completed
263 by MicrobesNG.

264 **Target Gene Over-Expression:** Target genes were cloned into the plasmid pMV261, under the control
265 of a constitutive promoter, in the presence of KAN (50 µg/mL) as selection marker. Compounds were
266 serially diluted 2-fold, to obtain a range covering the MIC at 50× the desired concentration, and 2 µl
267 was transferred across to 96-well Greiner black bottomed plates, leaving a single row moisture barrier
268 around the outside of the plate. BCG or Mtb strains, containing the pMV261 plasmids, were grown to
269 mid-log and diluted to 1.5×10^6 colony forming units (CFU)/mL. 98 µl of cells per well, was added to
270 the assay plates, which were sealed and incubated at 37˚C in a CO_2 incubator. After 7 days, 30 µl of a
271 0.02% (w/v) solution of resazurin and 12.5 µl of 20% tween-80 was added and the plates were incubated
272 overnight before measuring fluorescence (excitation at 530 nm and emission at 590 nm) using a
273 POLARstar Omega plate reader (BMG Labtech.). MICs of target gene over-expressing strains were
274 compared with a strain carrying a pMV261 empty vector. This method was also used to compare the
275 liquid MICs of the spontaneous mutants generated to those of the wild type (WT) strain of BCG.

276 **Drug Metabolism and Pharmacokinetics of FNDR-20081:**

Microsomal stability: Microsomal stability was performed using human and mouse liver microsomes. The final composition of the assay included 1 µM of FNDR-20081and the final concentration of DMSO was 0.1%, 0.125 mg/mL microsomal protein and cofactors (5.0 mM G-6-P, 0.06 U/mL G-6-PDH, 2.0 mM $MgCl_2$, 1.0 mM $NADP^+$). The compound was incubated with human and mouse liver microsomes with and without cofactors. The reaction mixture was removed at specified time points (0, 15, 30, 60 and 120 min) and the reaction was stopped by addition of ice-cold acetonitrile. The samples were extracted in presence of internal standard (Haloperidol) and were analyzed using LC-MS/MS. After the specified incubation period, percent of the remaining test/control compound was calculated with respect to the peak area ratio at time 0 min [7].

CYP3A4 inhibition: *In vitro* CYP3A4 enzyme inhibition assay was performed using human liver microsomes by probe substrate method. Serial dilutions of FNDR-20081 were prepared in potassium phosphate buffer (50 mM, pH 7.40) to obtain eight concentrations starting from 25 µM. The final composition of the assay mix was acetonitrile 1%, microsomal protein as 0.25 mg/mL, probe substrate (midazolam, 5 µM) and cofactors (5.0 mM G-6-P, 0.06 U/mL G-6-PDH, 2.0 mM of $MgCl_2$, 1.0 mM $NADP^+$). Serially diluted compound solutions and human liver microsomes were incubated for 10 min at 37°C with shaking. After pre-incubation, potassium phosphate buffer, probe substrate working solution and the cofactor mix was added. The reaction mixture was further incubated at 37°C with shaking (400 rpm) for 10 minutes. After incubation, reaction mixture was transferred to tubes containing stop solution (ice cold acetonitrile) and internal standard solution (Haloperidol), was centrifuged at 10000 rpm for 10 minutes at 4°C. The supernatant was transferred to vials and submitted for LC-MS/MS analysis of marker metabolite (OH-Midazolam). The % CYP Inhibition at different tested concentrations relative to vehicle control was calculated and IC_{50} value was determined.

Animals: The *in-vivo* studies for FNDR-20081 were carried out in strict accordance with recommendations of the Institutional Animal Ethics Committee (IAEC), registered with the Committee for the Purpose of Control and Supervision (CPCSEA), Government of India (registration no. 48/GO/Re-SL/BiS/99/CPCSEA). All the experimental protocols involving use of animals were reviewed and approved in advance by the IAEC. Carbon dioxide (CO_2) was used for euthanasia. The BALB/c mice aged between 6 to 8 weeks with an average body weight of 20-30 grams were used. Animals were housed in Individually ventilated cages (IVC's) in BSL-3 conditions. Animals were

306 randomly assigned to cages and allowed to acclimatize for 1 week prior to experiments. Feed and water
307 were provided *ad libitum*.

308 **Oral pharmacokinetics of FNDR-20081**: Single dose oral pharmacokinetic was established by
309 administering the compound (at 30 mg/kg and 300 mg/kg) in fasted adult male BALB/c mice (about 8-
310 10 weeks) formulated as suspension (in 5% (v/v) N,N-Dimethylacetamide (DMA), 5% Tween-80, 5%
311 propylene glycol and 85% sterile water for injection) by oral gavage. Blood samples were withdrawn at
312 specified intervals (Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours) into potassium –EDTA pre-coated
313 tubes. Blood was centrifuged at 13000 rpm for 10 mins, plasma was separated and analysed using LC-
314 MS/MS. Plasma samples were analyzed in LC-MS/MS and data was compiled by using non-
315 compartment analysis using Win-Nonlin [7].

316 **Pharmacokinetics (PK) in infected animals**: PK was performed on Day-26 post infection. Infected
317 animals were dosed once daily (30 mg/kg and 100 mg/kg). Blood samples were collected at different
318 time intervals (1, 2, 4, 8 and 24 h, post dosing). Blood was centrifuged, plasma was separated and
319 analysed using LC-MS/MS. Data was analysed by using non-compartment analysis using Winonlin.

320 ***In-vivo* Efficacy of FNDR-20081:**

321 **Dose response in chronic infection model.** BALB/c mice were infected via aerosol inhalation in a
322 Madison chamber calibrated to deliver 100 CFU/mouse lung [13]. Infected mice were housed in
323 isolators (Allentown technologies, USA) during the entire period of experimentation. Treatment began
324 4 weeks post infection. FNDR-20081 was administered once daily, by oral gavage in a vehicle (5% (v/v)
325 DMA + 5% (v/v) Tween 80 + 5% (v/v) propylene glycol + 85% (v/v) sterile water). Three doses, 10,
326 30 and 100mg/kg body weight were given 7 days a week, for a period of 4 weeks. RIF was used as a
327 positive control. On completion of dosing, animals were sacrificed 48 hours later by CO_2 narcosis, lungs
328 were removed, homogenized, and plated for enumeration of CFU/lung on Middlebrook 7H11 media
329 plates supplemented with OADC and PANTA (BD-245114). The plates were incubated at 37°C with
330 5% CO_2 for 3 weeks prior to reading bacterial CFU counts.
331

332

333

334 **Results**

335 **Chemistry- Lead identified as FNDR-20081:** A library of 60 compounds was synthesized. The
336 synthesis and preliminary SAR were reported earlier [7]. FNDR-20081 [4-{4-[5-(4-Isopropyl-phenyl)-
337 [1,2,4]oxadiazol-3-ylmethyl]-piperazin-1-yl}-7-pyridin-3-yl-quinoline] was selected (MIC 0.5-
338 2µg/mL) out of the quinoline series (Figure 1). FNDR-20081 series of compounds are novel and also
339 amenable to SAR with handles to modulate drug like properties. Its synthetic route is less than 7 steps
340 and therefore straightforward to scale up to multi gram production [7]. It is chemically stable, has no
341 obvious toxicophoric properties and no reactive functional groups. FNDR-20081 was identified as the
342 lead molecule for further progression.

343 FNDR-20081 is a small molecule with quinoline as a core (Figure 1). The quinoline has piperazine at
344 the C-4-position and a 3 pyridyl at C-7. The distal nitrogen on piperazine is further coupled to 1,2,4-
345 oxadiazole, which has a 4-isopropylphenyl at C-5. This is a unique scaffold with pyridine, quinoline,
346 piperazine and 1,2,4-oxadiazole present in tandem. The synthesis and detailed SAR, along with the ^{1}H
347 and ^{13}C NMR spectra was recently published [7]. FNDR-20081 was the most potent compound, hence
348 was selected for further progression.

349 **Minimum inhibitory concentration and bactericidal activity of FNDR-20081 on Mtb H37Rv**
350 **strain:** The compound demonstrated minimal inhibitory concentration (MIC) of 0.25-2µg/mL
351 (0.5µg/mL) and the minimal bactericidal concentration (MBC) as just 2-fold of MIC (i.e., 4µg/mL)
352 against *M. tuberculosis* H37Rv.

353 **Minimum inhibitory concentration of FNDR-20081 on drug resistant and sensitive Mtb strains:**
354 FNDR-20081 is a promising compound with potent MICs against clinical isolates of Mtb of variable
355 resistance profiles, with activity against sensitive, MDR and XDR strains. The MIC values of FNDR-
356 20081 against a total of 61 Mtb strains with a wide spectrum of drug sensitivity [XDR(5), MDR(33),
357 SDR (15), drug sensitive (8)] demonstrated very encouraging results. The MIC distribution was grouped
358 into two categories: Low MIC range (≤4µg/mL) and High MIC range (up to 16µg/mL) (Figure 2). The
359 MIC values were within 4-fold range as compared to the WT Mtb strain (≤ 4µg/mL) for all the XDR
360 strains, 91 % of MDR, 80 % of SDR and 87 % of the sensitive strains of MIC of FNDR-20081. A total
361 of 92% strains belonging to different resistance patterns fell under the category of Low MIC range
362 (≤4µg/mL), with MICs in the range of 1-16 µg/mL. None of the strains showed an MIC >16 µg/mL.

363 FNDR-20081 retained activity against clinical isolates that included susceptible, INH-resistant, EMB-
364 INH resistant, RIF-resistant and the other MDR/XDR isolates of Mtb.

365 **Drug Combination MIC assay:** The combination MIC of FNDR-20081 by checkerboard method
366 showed no antagonism with any of the first line, second line drugs or the new drugs tested (**Table 1**).
367 Drugs CLO and EMB showed synergism while all others exhibited indifference.

368 **MIC determination in the presence of serum/albumin to determine effect of protein binding:** MICs
369 of FNDR-20081 and the standard anti-TB drug, INH/RIF, in un-supplemented media, media
370 supplemented with 10% FBS and 10% BSA were determined to explore its protein binding capacity. In
371 the presence of 10% BSA, the MIC of FNDR-20081 changed marginally by 2-fold (2 μg/mL) *vs*. un-
372 supplemented media (1 μg/mL). The MICs of FNDR-20081 in the presence of 10% FBS and 10% BSA
373 (a physiologically equivalent concentration of albumin) were negligible, being only 2-fold higher, than
374 those in standard media. The MICs of INH and RIF also increased by 2- and 4-fold, respectively, under
375 these supplementations. Thus, the protein binding percentage capacity of FNDR-20081 was comparable
376 to that of reference anti-TB drugs.

377 The MIC of FNDR-20081 did not increase significantly when tested in protein rich (FCS and BSA) *vs.*
378 the non-protein rich media. The MIC was changed only by 2-fold (2μg/mL) in FCS and BSA containing
379 media (**Table 2**).

380 **Mycobactericidal activity of FNDR-20081 on replicating Mtb:** Bacterial colony forming units (cfu)
381 were enumerated, data was compiled, and the kill curve graphs were generated (Figure 3) by plotting
382 Log_{10} CFU/mL values against time (h) in GraphPad Prizm v5.0.

383 *In-vitro* killing kinetics studies play an important role in determining the PKPD drivers for antibacterial
384 activity and measuring maximum efficacy (E_{max}) at various drug exposures. We have previously profiled
385 PKPD parameters for anti-TB drugs and determined the PD driver for efficacy [13,14,15]
386 recommending it for all the new compounds for their effective usage and suppression of drug resistance
387 [13]. To investigate the killing kinetics of FNDR-20081 for determining the PD driver, 14-day kill-
388 kinetics studies were performed using serial 4-fold dilutions (256-0.5μg/mL) against *M. tuberculosis*
389 H37Rv. The kinetic kill-curve was generated by plotting log_{10} CFU vs. time at all concentrations (Figure
390 3). FNDR-20081 displayed bactericidal effects with an Emax of 2.1 log_{10} cfu/mL (Figure 3).

391 FNDR-20081 demonstrates increased kill with increasing concentrations (concentration-dependent) as
392 well as after longer durations of exposures to the compound (time-dependent). The pattern of killing is
393 very similar to the standard anti-TB drug RIF (and the superior drug Bedaquiline which is not compared
394 in these models), which is one of the strongest known bactericidal anti-TB drugs under replicating as
395 well as the non-replicating (NRP) conditions; reflecting the bactericidal potential of FNDR-20081 for
396 the optimal treatment in clinical situations since Mtb exists under multiple replicating and non-
397 replicating phases.

398 **Mycobactericidal activity of FNDR-20081 on non-replicating Mtb:** FNDR-20081 demonstrated a
399 reasonable activity under low pH conditions, the most important intra-granuloma milieu for Mtb to
400 survive and propagate [17]; reducing the Mtb load by 1.2 log_{10} cfu/mL, FNDR-20081 also reduced the
401 population of as well as on the nutritionally starved Mtb by 0.7 log_{10} cfu/mL. However, under stationary
402 phase it showed a negligible (0.2log_{10} cfu/mL) cfu reduction (**Table 3**).

403 **Cytotoxicity of FNDR-20081:** Cytotoxicity of the compound was tested on HepG2 and PMA-activated
404 THP-1 macrophage cell lines [12] at 2-fold diluted compound concentrations (64-0.125 µg/mL). The
405 colorimetric readout confirmed that FNDR-20081 did not demonstrate any toxicity to THP-1 as well as
406 HepG2 cells even up to 32X MIC (cytotoxicity >64 µg/mL).

407 **Intracellular efficacy of FNDR-20081:** The intracellular mycobacterial killing rates of FNDR-20081
408 and the control drug rifampicin were determined [12] by nonlinear regression analysis (95% confidence
409 limits). Inhibitory curves were generated by plotting the log_{10} cfu/mL against the Day-0, 3, 5 and 7. The
410 Emax observed was 1.5 log_{10}cfu/mL (Figure 4)

411 **Activity of FNDR-20081 on Mtb in modified media/conditions:** FNDR-20081 was found to be active
412 on Mtb growing under all the different nutrient source conditions, required for cell wall biosynthesis,
413 hence, very unlikely to target cell wall biosynthesis (**Table 4**). This data suggests that FNDR-20081
414 may be efficacious against Mtb *in-vivo* in the granuloma as well.

415 **Target identification of FNDR-20081:**

416 **Activity of FNDR-20081 on cell wall target over-expression in BCG:** Among the cell wall targets,
417 initial studies to determine the mechanism of action of FNDR-20081 indicated that the compound does
418 not target DprE1 (Figure 5). Over-expression of DprE1 in BCG shifts the MIC of the control compound

419 BTZ043 (known to target DprE1) by more than 16× (from 0.004 µg/mL to >0.064 µg/mL), when
420 compared to cells with the pMV261 vector control. However, over-expression of DprE1 did not alter
421 the MIC of FNDR-20081. In addition, there was no effect on the MIC of FNDR-20081 for resistant
422 mutants generated to GSK303, another compound known to target DprE1 [18].

423 **FNDR-20081 Spontaneous Resistance Mutants in *M. bovis* BCG:** A systematic approach to target
424 identification was adopted by the generation of spontaneous mutants. The MIC of FNDR-20081, for *M.*
425 *bovis* BCG grown on solid media, was 6.25 µg/mL. Spontaneous resistant mutants grew at 5×, 10× and
426 20× MIC of FNDR with frequencies of resistance (FoR) of 7×10^{-8}, 12×10^{-8} and 19×10^{-8}, respectively.
427 The genomes of four resistant mutants (one from 10× and three from 5× MIC) were sequenced and
428 aligned to the genome of the parental strain to determine the mutations that could give rise to resistance.
429 All four mutants carried mutations in the *marR* regulator (BCG_0727, corresponding to Rv0678 in Mtb):
430 a mutation in three of the mutants introduced a stop codon thereby interrupting gene expression; the
431 other mutant had an insertion, resulting in a frame shift.

432 Since *MarR* regulates the expression of MmpL5, which is known to confer resistance to other drugs,
433 such as azoles [19,20] through extrusion methods, cross-resistance of these *marR* mutants to an azole
434 (clotrimazole, CLT) was compared to new spontaneous mutants generated to FNDR-20081 (Figure 6).
435 The mutants with mutations in *marR* all demonstrated cross-resistance to CLT, with a 2-fold increase in
436 MIC compared to the WT strain (25 *vs*. 12.5 µg/mL). However, there were three new mutants, resistant
437 to FNDR-20081, with no cross-resistance to CLT. Mutations of all three mutants mapped to Rv3683, a
438 metallophosphoesterase (Supplement Table S-1).

439 **Activity of FNDR-20081 against ESKAPE pathogens:** FNDR-20081 demonstrated a highly TB-
440 specific activity. There was no MIC against any of the ESKAPE pathogens panel tested (**Table -5**).

441 **Drug Metabolism and Pharmacokinetics:**

442 **Microsomal stability and CYP3A4 inhibition**: The percentage of the compound remaining in the
443 reaction mixture after specified incubation period was calculated with respect to the peak area ratio at
444 time 0 min. FNDR-20081, was actively metabolized in mouse liver microsomes (<5% remaining at 60
445 min), however it was moderately stable in human liver microsomes (40% remaining at 60 min) [7].

446 In addition, the CYP3A4 inhibition assay with FNDR-20081 revealed no CYP3A4 liability and the IC_{50}
447 was >25 µM. Other compounds in the series demonstrated CYP3A4 inhibition at <2µM.
448 **Oral pharmacokinetics of FNDR-20081**: Mean plasma concentrations of FNDR-20081 at 30 mg/kg
449 and 300 mg/kg doses are shown in Figure 7. Orally bioavailable, a saturable absorption was observed
450 for the compound (Cmax) of 7.4 µg/mL for the 30 mg/kg dose and 13.8 µg/mL for the 300 mg/kg dose
451 group. There was a dose proportional increase in plasma exposures. AUC_{inf} for the 30 mg/kg dose was
452 11.9 h*µg/mL and for the 300 mg/kg bw was 103.775 h*µg/mL.

453 **Pharmacokinetics in infected animals:**

454 The mean plasma concentration of FNDR-20081 administered at 30 mg/kg and 100 mg/kg bw p.o. doses
455 were plotted (Figure 8). A 30mg/kg dose resulted in a Cmax of 3.2µg/mL which increased proportionally
456 to 14.2µg/mL for the 100mg/kg dose; this which was equivalent to the 300 mg/kg dose in uninfected
457 animals. The Cmax remained several folds above the MIC following repeat dosing. Similarly, there was
458 increase in AUC_{last} following repeat dosing of the compound (Figure 8A). A significant increase in MRT
459 was observed from the 30mg/kg dose (4.7 h) to the 100 mg/kg dose (7.67 h).

460 ***In-vivo*** **Efficacy of FNDR-20081:**

461 Based on ADME studies, FNDR-20081 was progressed for testing the *in-vivo* efficacy in the chronic
462 mouse infection model of tuberculosis. Oral doses of 10, 30 and 100 mg/kg were tested. Treatment with
463 FNDR-20081, was well tolerated in mice. There was no reduction in lung loads at 10 and 30 mg/kg
464 doses but treatment with 100 mg/kg resulted in 0.6 log_{10} CFU/lung (significant, $p<0.05$) reduction in
465 bacterial counts (Figure 9). PK/PD correlations showed that PK parameters increased significantly for
466 the 100mg/kg bw dose (Cmax: 14.2µg/ml and plasma AUC_{last} 69.5 h*µg/ml) and resulted in *in-vivo*
467 efficacy. This suggested that efficacy is driven by PK parameters. RIF (30 mg/kg) used as a positive
468 control drug reduced the bacterial loads by 3 log_{10} CFU/lung.

469

470

471

472

473 **Discussion**

474 Anti-microbial resistance (AMR) has posed major challenges in the clinical management of infectious
475 diseases and shaken the health-care infrastructure. Tuberculosis alone has ~550,000 cases of MDR and
476 XDR-TB and the overall cases have not declined much in recent years [1]. Although there are multiple
477 reasons that drive the emergence of MDR, a major factor is the non-availability of new drugs targeting
478 novel mechanisms. There is a plethora of old drugs, their toxicity and long treatment duration invariably
479 results in poor compliance that leads to drug resistance. We need safer drugs targeting new mechanisms
480 to combat the MDR-TB threat. There is an urgent medical need to combat the TB pandemic by
481 developing novel and safer anti-tubercular drugs targeting pan-TB: sensitive, (S) multiple drug resistant
482 tuberculosis (MDR-TB) and extensively drug resistant cases of tuberculosis (XDR-TB).
483 We discovered a novel, first in class anti-TB compound FNDR-20081 and hypothesized that it may play
484 a key role in the treatment of active and latent (non-replicating) forms of TB and enable TB-eradication
485 goals. We sought to design and explore quinoline in combination with piperazine and oxadiazole
486 moieties, which makes FNDR-20081 an exclusive TB-specific inhibitor. This compound seems to have
487 a distinct mechanism of action, with potent pan-TB activity irrespective of their resistance profile (MDR,
488 XDR). More than 90% of the clinical isolates of variable sensitivity profiles had MIC in the low range
489 ($\leq$4µg/mL) indicating its target novelty. Though quinolines and oxadiazoles have previously
490 independently been reported to be antibacterial [21], as well as antimycobacterial agents [22-35], their
491 oral exposure suggested solubility limited drug absorption in addition to the first pass metabolism
492 problems. Piperazine compounds [36-38] have also been reported as potent anti-TB agents against
493 MDR-TB.

494 We could successfully generate spontaneous mutants to the compound. Initially, mutations disrupted the
495 expression of *marR*, a Mar-like (multiple antibiotic resistance) transcriptional repressor Rv0678
496 [20,39,40] responsible for the regulation of the *mmpS5-mmpL5* operon [19]. Mutations within this
497 regulator have also been linked with resistance to azoles [19]. These mutations were shown to upregulate
498 expression of *mmpS5-mmpL5* operon and coincided with a reduced level of azoles measured within the
499 cytoplasm of the mutants, leading the authors to speculate that this region may encode an efflux pump
500 [19] (*Milano et al., 2009*). Indirectly or directly MmpL5 along with MmpL4 has also been reported to
501 block iron transport through mycobacterial siderophores (mycobactins and carboxymycobactins,
502 [20,41,42]) leading to siderophore mediated suicidal intracellular pools. These Mtb mutants generated

503 against FNDR-20081 do demonstrate cross-resistance to CLT. But interestingly, in the other three
504 subsequent spontaneous mutants to FNDR-20081, that had no mutations in *marR* and were not cross-
505 resistant to CLT, mapped to BCG_3742, corresponding to Rv3683 in Mtb. Rv3683 is a
506 metallophosphoesterase, while non-essential by transposon site hybridization (TraSH) [43], the location
507 of Rv3683 to a penicillin binding protein (PBP) on the genome could form part of a more significant
508 interaction with this protein and peptidoglycan biosynthesis. Additional studies will be required to
509 further validate Rv3683 also as a target of FNDR-20081.

510 Undoubtedly, MDR can be counteracted by targeting novel targets using combination of novel
511 drugs/chemical entities. A recent study by Conradie et al. (2020) and Global Alliance for TB has
512 unequivocally confirmed this hypothesis [4]. A combination of three recently developed new drugs
513 Bedaquiline, Pretomanid and Linezolid (BPaL) reduced treatment of MDR-TB from usual 24 months to
514 6 months [4]. This is the first evidence after 70 years that MDR-TB can be treated in shorter periods
515 with the potency of new drugs targeting novel bacterial targets. This has brought in a new paradigm that
516 MDR-TB may not be necessarily hard to treat, provided that we can hit new bactericidal targets with
517 new chemical scaffolds.

518 Another emerging concept that could impact treatment of MDR-TB is multitarget therapy [4]. "Multi-
519 targeting" therapy, with a single drug is epitomized to be a preferred approach over conventional mono-
520 targeting [20,44-48]. Many of the successful anti-TB regimen drugs (e.g., isoniazid, ethambutol,
521 pyrazinamide and Pretomanid) [48] as well as another drug in the pipeline, ethylene diamine drug,
522 SQ109 (an uncoupler inhibiting two distinct proteins involved in cell wall and menaquinone
523 biosynthesis (Mmpl3, MenA and MenG, and ATP biosynthesis proteins) exhibit multi-targeting
524 phenomenon [48-50]. Among the existing drugs, coumarins (e.g., Novobiocin), inhibit DNA
525 topoisomerases along with Fad24 and FtsZ [49]. Such multi-targeting drugs are powerful tools to tackle
526 multi-drug-resistance. FNDR-20081 also probably hits multiple targets within the cell wall such as
527 regulator of *mmpS5-mmpL5* and a metallo-phosphoesterases. However, more intricate studies are
528 required to confirm the targets with identification of the precise ligand binding site. It may provide an
529 opportunity to develop new combinations against drug resistant Mtb.

530 The pathogen and the host have co-evolved with a strong association towards manipulating a fine
531 balance in establishing the disease or no-disease; and dissemination or persistence [16,51]. Mtb
532 encounters hostile conditions under both extracellular as well as intracellular milieu in the host and may

533 consequently adopt a replicating or a non-replicating phenotype [16,17,52]. One-quarter of the world's
534 population is infected with a latent form of TB which is presumed to be non-replicating and
535 metabolically inactive phenotype [1]. Non-replicating populations (NRP) are produced under *in-vitro*
536 stress conditions (acidic, nutrient starvation, oxygen deprivation, stationary phase conditions as well as
537 in macrophages) [8,16,17,52]. These non-replicating forms are unusually drug tolerant. Interestingly,
538 FNDR-20081 is active against all the phenotypes of Mtb (Table 3). Multitargeting seems to be an
539 emerging concept in TB drugs. All recently discovered anti-TB drugs (Bedaquiline, Pretomanid and
540 Delamanid) hit multiple targets and are active against both replicating and non-replicating populations
541 of Mtb [53,54]. FNDR-20081 is bactericidal, killed >2$\log_{10}$ CFU of replicating Mtb in an exposure-
542 dependent manner at day-14. However, the kill was not saturated suggesting that FNDR-20081 may
543 indeed have even better bactericidal potential.

544 The ability of FNDR-20081 to kill nonreplicating Mtb (NRP-Mtb) under different physiological
545 conditions along with the desirable PK properties showed translation into *in-vivo* efficacy in the chronic
546 TB infection model harboring mixed populations of replicating and NRP-Mtb in the lungs of mice. This
547 effect of FNDR-20081 on NRP forms in mice gives us optimism that it will likewise kill the
548 dormant/persistent bacteria in latently infected human patients.

549 Metabolic studies in human and mouse microsomes revealed FNDR-20081 to be unstable (moderate in
550 HLM and poor in MLM) suggesting the role of hepatic metabolism in the elimination of compound [7].
551 Nevertheless, plasma Cmax levels were above the MIC with high plasma exposures for most of the
552 doses that resulted in *in-vivo* efficacy.

553 The PK levels above the MIC translated into bacterial reduction by 0.56 $\log_{10}$ CFU/lung at a 100 mg/kg
554 dose. A significant increase in AUC/MIC (8-fold) as well as time/MIC (1.7-fold) observed for the 100
555 mg/kg bw dose may be the key factor driving efficacy as compared to the 10 mg/kg and 30 mg/kg
556 dosing. The data further strengthened the *in-vitro* observation of exposure (concentration- as well as
557 time)- driven efficacy in kill kinetics experiments. Based on proportionally higher PK exposure observed
558 at 300 mg/kg, we firmly believe that the *in-vivo* efficacy can be improved further at higher doses.

559 FNDR-20081 is a highly TB-specific preclinical candidate that can be optimized further into a clinical
560 candidate. An exclusive use of this molecule against MDR TB probably will give an opportunity for a
561 restricted use to avoid an indiscriminate use leading to emergence of resistance.

To conclude, we report FNDR-20081, a novel first in class oral compound with a multitargeting mechanism of action, acting on a transcriptional repressor responsible for regulation of *mmpS5-mmpL5* operon and a metallo-phospho-esterase that needs to be intricately delineated further. FNDR-20081 is active against replicating and non-replicating populations of TB under *in-vitro*, intra-macrophage, and *in-vivo* conditions. In addition, compatibility for combination therapy and no drug-drug interaction of FNDR-20081 with existing TB drugs supports possibility of developing novel anti-TB drug regimens.

Therefore, next, we plan to test the *in-vivo* efficacy at the higher tolerable dose of 300mg/kg bw and in combination with the 1st line, 2nd line TB drugs, as well as with the new drugs recently entered in clinical use such as Bedaquiline, Pretomanid and Linezolid (BPaL). In parallel, further studies to investigate its potential to shorten duration of treatment time needs to be explored.

Funding

This study was funded by Foundation for Neglected Disease Research.

Declaration of competing interest

The authors declare no competing interests.

ACKNOWLEDGEMENTS

The authors would like to acknowledge Mr. Mayas Singh from FNDR for facilitating the project activities.

617 **REFERENCES**

618 1. World Health Organization. Global tuberculosis report 2020. Geneva. World Health Organization;
619 2020. https://www.who.int/tb/publications/global_report/en/
620 2. https://tbfacts.org/end-tb/
621 3. Centers for Disease Control and Prevention. Tuberculosis (TB).
622 https://www.cdc.gov/tb/default.htm
623 4. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira
624 J, Timm J, McHugh TD, Wills GH, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M,
625 Spigelman M; Nix-TB Trial Team. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
626 New Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814.PMID: 32130813.
627 5. Vadim M, Salina E, Reynolds RC, Zin PPK, Ekins S. 2020. Molecule Property Analyses of Active
628 Compounds for Mycobacterium Tuberculosis. J Med Chem (Just Accepted Manuscript). DOI:
629 10.1021/acs.jmedchem.9b02075.
630 6. https://clinicaltrials.gov/ct2/show/NCT04176250
631 7. Shruthi TG, Eswaran S, Shivarudraiah P, Narayanan S, Subramanian S. 2019. Synthesis,
632 antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-
633 oxadiazole moiety. Bioorg Med Chem Lett 29:97-102. doi: 10.1016/j.bmcl.2018.11.002
634 8. Kaur P, Potluri V, Ahuja VK, Naveenkumar CN, Shruthi TG, Shivarudraiah P, Eswaran S, Shandil
635 RK, Narayanan S. 2019. FNDR-20081- A Novel Pre-Clinical Candidate for Treatment of TB/MDR
636 Tuberculosis. AAR# 736, 21st June 2019, Control #: 5054, ASM Microbe 2019. June 20-24, 2019
637 San Francisco, CA.
638 9. CLSI- Clinical and Laboratory Standards Institute (CLSI), Susceptibility testing of Mycobacteria,
639 Nocardia, and other aerobic actinomycetes 940 West Valley Road, Suite 1400, Wayne, PA 19087
640 USA.
641 10. Franzblau SG, Witzig RS, Mclaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook
642 MB, Quenzer VK, Ferguson RM, Gilman RH. 1998. Rapid, low-technology MIC determination with
643 clinical *Mycobacterium tuberculosis* isolates by using the microplate Alamar Blue assay. J Clin
644 Microbiol 36:362-366. doi:10.1128/JCM.36.2.362-366.1998
645 11. Kaur P, Ghosh A, Krishnamurthy RV, Bhattacharjee DG, Achar V, Datta S, Shridhar N, Anand A,
646 Ramaiah S. 2015. A High-Throughput Cidality Screen for *Mycobacterium Tuberculosis*. PLoS ONE
647 10: e0117577. doi:10.1371/journal.pone.0117577. https://doi.org/10.1371/journal.pone.0117577.

648 12. Shirude PS, Shandil R, Sadler C, Naik M, Hosagrahara V, Hameed S, Shinde V, Bathula C,
649 Humnabadkar V, Kumar N, Reddy J, Panduga V, Sharma S, Ambady A, Hegde N, Whiteaker J,
650 McLaughlin RE, Gardner H, Madhavapeddi P, Ramachandran V, Kaur P, Narayan A, Guptha S,
651 Awasthy D, Narayan C, Mahadevaswamy J, Vishwas KG, Ahuja V, Srivastava A, Prabhakar KR,
652 Bharath S, Kale R, Ramaiah M, Choudhury NR, Sambandamurthy VK, Solapure S, Iyer PS,
653 Narayanan S, Chatterji M. 2013. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing
654 efforts kill *Mycobacterium tuberculosis* and are efficacious *in vivo*. J Med Chem 56:9701-8. DOI:
655 10.1021/jm401382v.
656 13. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath
657 S, Balasubramanian V. 2007. Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against
658 Mycobacterium tuberculosis: Evaluation of in vitro and pharmacodynamic indices that best predict
659 *in vivo* efficacy. Antimicrob Agents Chemother 51:576-582. doi: 10.1128/AAC.00414-06.
660 14. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi N, Bharat S, Shandil
661 RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetic-pharmacodynamic relationships for
662 rifampicin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47:2118-
663 2124. DOI: 10.1128/aac.47.7.2118-2124.2003.
664 15. Jayaram R, R. K. Shandil, Sheshagiri Gaonkar, Parvinder Kaur, B.L. Suresh, B.N. Mahesh, R.
665 Jayashree, Vrinda Nandi, Sowmya Bharat, E. Kantharaj, and V. Balasubramanian. 2004. Isoniazid
666 pharmacokinetics-pharmacodynamics in aerosol infection model of tuberculosis. Antimicrob Agents
667 Chemother 48:2951-57. doi: 10.1128/AAC.48.8.2951-2957.2004
668 16. Kaur P, Datta S, Shandil RK, Kumar N, Robert N, Sokhi UK, Guptha S, Narayanan S, Anbarasu A,
669 Ramaiah S. 2016. Unravelling the secrets of mycobacterial cidality through the lens of antisense.
670 PLoS ONE 11:e0154513. doi:10.1371/journal.pone.0154513.
671 17. Early JV, Mullen S, Parish T. 2019. A rapid, low pH, nutrient stress, assay to determine the
672 bactericidal activity of compounds against nonreplicating *Mycobacterium tuberculosis*. PLoS ONE
673 14:e0222970. https://doi.org/10.1371/journal.pone.0222970
674 18. Batt SM, Cacho IM, Pichel CJ, Stubbs CJ, Vela-Glez Del Peral L, Pérez-Herrán E, Dhar N, Mouzon
675 B, Rees M, Hutchinson JP, Young RJ, McKinney JD, Barros Aguirre D, Ballell L, Besra GS,
676 Argyrou A. 2015. Whole cell target engagement identifies novel inhibitors of *Mycobacterium*
677 *tuberculosis* decaprenylphosphoryl-β-d-ribose oxidase. ACS Infect Dis. 1:615-626. doi:
678 10.1021/acsinfecdis.5b00065.

679 19. Milano A, Pasca MR, Provvedi R, Lucarelli AP, Manina G, Ribeiro AL, Manganelli R, Riccardi G.
680 2009. Azole resistance in *Mycobacterium tuberculosis* is mediated by the MmpS5-MmpL5 efflux
681 system. Tuberculosis (Edinb.) 89:84–90. http://dx.doi.org/10.1016/j.tube.2008.08.003.
682 20. Hartkoorn RC, Uplekar S, Cole ST. 2014. Cross-Resistance between Clofazimine and Bedaquiline
683 through Upregulation of MmpL5 in *Mycobacterium tuberculosis*. Antimicrob Agents Chemother
684 58:2979–2981. doi: 10.1128/AAC.00037-14.
685 21. Upadhayaya RS, Vandavasi JK, Vasireddy NR, Sharma V, Dixit SS, Chattopadhyaya J. 2009.
686 Design, synthesis, biological evaluation, and molecular modelling studies of novel quinoline
687 derivatives against *Mycobacterium tuberculosis*. Bioorg Med Chem 17:2830–2841. DOI:
688 10.1016/j.bmc.2009.02.026.
689 22. de Souza MV, Pais KC, Kaiser CR, Peralta MA, de L Ferreira M, Lourenço MC.2009. Synthesis
690 and in vitro antitubercular activity of a series of quinoline derivatives. Bioorg Med Chem 17:1474-
691 1480. doi: 10.1016/j.bmc.2009.01.013. Epub 2009 Jan 15.PMID: 19188070
692 23. Sanchez JP, Domagala JM, Hagen SE, Heifetz CL, Hutt MP, Nichols JB, Trehan AK. 1988.
693 Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted
694 quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids. J Med Chem 31:983-91.
695 DOI: 10.1021/jm00400a016.
696 24. Lilienkampf A, Mao J, Wan B, Wang Y, Franzblau SG, Kozikowski AP. 2009. Structure-activity
697 relationships for a series of quinoline-based compounds active against replicating and nonreplicating
698 *Mycobacterium tuberculosis*. J Med Chem 52:2109-18. doi: 10.1021/jm900003c. PMID: 19271749
699 25. Marganakop SB, Kamble RR, Taj T, Kariduraganvar MY. 2012. An efficient one-pot cyclization of
700 quinoline thiosemicarbazones to quinolines derivatized with 1,3,4-thiadiazole as anticancer and anti-
701 tubercular agents. Med Chem Res 21:185–191. DOI:10.1007/s00044-010-9522-z.
702 26. Eswaran S, Adhikari AV, Chowdhury IH, Pal NK, Thomas KD. 2010. New quinoline derivatives:
703 synthesis and investigation of antibacterial and antituberculosis properties. Eur J Med Chem
704 45:3374-3383. doi: 10.1016/j.ejmech.2010.04.022.
705 27. Pissinate K, Villela AD, Rodrigues-Junior V, Giacobbo BC, Grams ES, Abbadi BL, Trindade RV,
706 Roesler Nery L, Bonan CD, Back DF, Campos MM, Basso LA, Santos DS, Machado P. 2016. 2-
707 (Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant
708 *Mycobacterium tuberculosis* Strains. ACS Med Chem Lett 7:235-239.
709 doi:10.1021/acsmedchemlett.5b00324. eCollection 2016 Mar 10.

710 28. Giacobbo BC, Pissinate K, Rodrigues-Junior V, Villela AD, Grams ES, Abbadi BL, Subtil FT,
711 Sperotto N, Trindade RV, Back DF, Campos MM, Basso LA, Machado P, Santos DS. 2017. New
712 insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against
713 *Mycobacterium tuberculosis*. Eur J Med Chem. 126:491-501. doi: 10.1016/j.ejmech.2016.11.048.
714 29. Phummarin N, Boshoff HI, Tsang PS, Dalton J, Wiles S, Barry Rd CE, Copp BR. 2016. SAR and
715 identification of 2-(quinolin-4-yloxy)acetamides as *Mycobacterium tuberculosis* cytochrome bc1
716 inhibitors. Med Chem Comm 7:2122-2127. doi: 10.1039/c6md00236f.
717 30. Martinez-Grau MA, Valcarcel ICG, Early JV, Gessner RK, de Melo CS, de la Nava EMM,
718 Korkegian A, Ovechkina Y, Flint L, Gravelle A, Cramer JW, Desai PV, Street LJ, Odingo J,
719 Masquelin T, Chibale K, Parish T. 2018. Synthesis and biological evaluation of aryl-oxadiazoles as
720 inhibitors of *Mycobacterium tuberculosis*. Bioorg Med Chem Lett 28:1758-1764. doi:
721 10.1016/j.bmcl.2018.04.028.
722 31. Kumar RR, Perumal S, Menéndez JC, Yogeeswari P, Sriram D. 2011. Antimycobacterial activity of
723 novel 1,2,4-oxadiazole-pyranopyridine/chromene hybrids generated by chemoselective 1,3-dipolar
724 cycloadditions of nitrile oxides. Bioorg Med Chem 19:3444-3450. DOI:
725 10.1016/j.bmc.2011.04.033.
726 32. Almansour AI, Suresh Kumar R, Arumugam N, Sriram DA. 2012. Solvent free, four component
727 synthesis and 1,3-dipolar cycloaddition of 4(h)-pyrans with nitrile oxides: Synthesis and discovery
728 of antimycobacterial activity of enantiomerically pure 1,2,4-oxadiazoles. Eur J Med Chem 53:416-
729 423.
730 33. Rane RA, Gutte SD, Sahu NU. 2012. Synthesis and evaluation of novel 1,3,4-oxadiazole derivatives
731 of marine bromopyrrole alkaloids as antimicrobial agent. Bioorg Med Chem Lett 22:6429-32. doi:
732 10.1016/j.bmcl.2012.08.061.
733 34. Karabanovich G, Zemanová J, Smutný T, Székely R, Šarkan M, Centárová I, Vocat A, Pávková I,
734 Čonka P, Němeček J, Stolaříková J, Vejsová M, Vávrová K, Klimešová V, Hrabálek A, Pávek P,
735 Cole ST, Mikušová K, Roh J. 2016. Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles
736 and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating
737 *Mycobacterium tuberculosis*. J Med Chem 59:2362-80. doi: 10.1021/acs.jmedchem.5b00608.
738 35. Karabanovich G, Němeček J, Valášková L, Carazo A, Konečná K, Stolaříková J, Hrabálek A, Pavliš
739 O, Pávek P, Vávrová K, Roh J, Klimešová V. 2017. S-substituted 3,5-dinitrophenyl 1,3,4-

740 oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. Eur J Med Chem
741 126:369-383. doi: 10.1016/j.ejmech.2016.11.041.
742 36. Bhakta S, Scalacci N, Maitra A, Brown AK, Dasugari S, Evangelopoulos D, McHugh TD, Mortazavi
743 PN, Twist A, Petricci E, Manetti F, Castagnolo D. 2016. Design and Synthesis of 1-((1,5-Bis(4-
744 chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-
745 2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives:
746 Discovery of Potent Antitubercular Agents Effective against Multidrug-Resistant Mycobacteria. J
747 Med Chem 59:2780-93. doi: 10.1021/acs.jmedchem.6b00031.
748 37. Naidu KM, Srinivasarao S, Agnieszka N, Ewa AK, Kumar MM, Chandra Sekhar KV. 2016. Seeking
749 potent anti-tubercular agents: Design, synthesis, anti-tubercular activity and docking study of
750 various ((triazoles/indole)-piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole derivatives. Bioorg
751 Med Chem Lett. 26:2245-50. doi: 10.1016/j.bmcl.2016.03.059.
752 38. Thomas KD, Adhikari AV, Chowdhury IH, Sumesh E, Pal NK. 2011. New quinolin-4-yl-1,2,3-
753 triazoles carrying amides, sulphonamides and amidopiperazines as potential antitubercular agents.
754 Eur J Med Chem. 46:2503-12. doi: 10.1016/j.ejmech.2011.03.039. Epub 2011 Apr 13. PMID:
755 21489660
756 39. Poole K, Tetro K, Zhao Q, Neshat S, Heinrichs DE, Bianco N. 1996. Expression of the multidrug
757 resistance operon mexA–mexB–oprM in *Pseudomonas aeruginosa*: mexR encodes a regulator of
758 operon expression. Antimicrob Agents Chemother 40:2021–8.
759 40. Tekaia F, Gordon SV, Garnier T, Brosch R, Barrell BG, Cole ST. 1999. Analysis of the proteome
760 of *Mycobacterium tuberculosis* in silico. Tubercle Lung Dis. 79:329–342.
761 http://dx.doi.org/10.1054/tuld.1999.0220
762 41. Wells RM, Jones CM, Xi Z, Speer A, Danilchanka O, Doornbos KS, Sun P, Wu F, Tian C,
763 Niederweis M. 2013. Discovery of a siderophore export system essential for virulence of
764 *Mycobacterium tuberculosis*. PLoS Pathog. 9:e1003120.
765 http://dx.doi.org/10.1371/journal.ppat.1003120.
766 42. Jones CM, Wells RM, Madduri AV, Renfrow MB, Ratledge C, Moody DB, Niederweis M. 2014.
767 Self-poisoning of *Mycobacterium tuberculosis* by interrupting siderophore recycling. Proc Natl
768 Acad Sci USA. 111:1945–1950. http://dx.doi.org/10.1073/pnas.1311402111

769 43. Sassetti CM, Boyd DH, Rubin EJ (2003). Genes required for mycobacterial growth defined by high
770 density mutagenesis. Mol Microbiol 48(1):77–84. PMID: 12657046. DOI: 10.1046/j.1365-
771 2958.2003.03425.x
772 44. Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, Fontes FL, Yang H, Rao
773 G, Zhu W, Gulati A, No JH, Cintra G, Bogue S, Liu YL, Molohon K, Orlean P, Mitchell DA, Freitas-
774 Junior L, Ren F, Sun H, Jiang T, Li Y, Guo RT, Cole ST, Gennis RB, Crick DC, Oldfield E. 2014.
775 Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 57:3126–
776 3139, https://doi.org/10.1021/jm500131s (2014),
777 45. Laurent R. Chiarelli, Giorgia Mori, Beatrice Silvia Orena, Marta Esposito, Thomas Lane, Ana Luisa
778 de Jesus Lopes Ribeiro, Giulia Degiacomi, Júlia Zemanová, Sára Szádocka, Stanislav Huszár,
779 Zuzana Palčeková, Marcello Manfredi, Fabio Gosetti, Joël Lelièvre, Lluis Ballell, Elena Kazakova,
780 Vadim Makarov, Emilio Marengo, Katarina Mikusova, Stewart T. Cole, Giovanna Riccardi, Sean
781 Ekins & Maria Rosalia Pasca 2018. A multitarget approach to drug discovery inhibiting
782 Mycobacterium tuberculosis PyrG and PanK. Scientific Reports volume 8, Article number: 3187
783 46. Chiarelli LR, Mori G, Orena BS, Esposito M, Lane T, Luisa de A, Ribeiro JL, Degiacomi G,
784 JZemanová J, Szádocka S, Huszár S, Palčeková Z, Manfredi M, Gosetti F, Lelièvre J, Ballell L,
785 Kazakova E, Makarov V, Marengo E, Mikusova K, Cole ST, Riccardi G, Ekins S, Pasca MR. 2018.
786 A multitarget approach to drug discovery inhibiting *Mycobacterium tuberculosis* PyrG and PanK.
787 Scientific Reports :8, Article number:3187. https://doi.org/10.1038/s41598-018-21614-4.
788 47. Makarov, V., Salina, E., Reynolds, R. C., Kyaw Zin, P. P., & Ekins, S. (2020). Molecule Property
789 Analyses of Active Compounds for *Mycobacterium Tuberculosis*. Journal of Medicinal Chemistry.
790 doi:10.1021/acs.jmedchem.9b02075
791 48. Mabhula A, Singh V. 2019. Drug-resistance in *Mycobacterium tuberculosis*: where we stand. Med
792 Chem Comm. 10:1342-1360. doi: 10.1039/c9md00057g. eCollection 2019 Aug 1. Review. PMID:
793 31534654.
794 49. Viana Jessika de Oliveira, Hamilton Mitsugu Ishiki, Marcus Tullius Scotti, and Luciana Scotti
795 (2018). Multi-Target Antitubercular Drugs. Current Topics in Medicinal Chemistry, 2018, 18, 1-8.
796 50. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D,
797 Barry CE 3rd, Boshoff HI. 2019. SQ109 targets MmpL3, a membrane transporter of trehalose
798 monomycolate involved in mycolic acid donation to the cell wall core of *Mycobacterium*

tuberculosis. Antimicrob Agents Chemother. 2012 Apr;56(4):1797-809. doi: 10.1128/AAC.05708-11. Epub 2012 Jan 17. PMID: 22252828.

51. Shapira T, Rankine-Wilson L, Chao J, Pichler V, Rens C, Pfeifer T, Av-Gay Y. 2020. High-Content Screening of Eukaryotic Kinase Inhibitors 1 identify CHK2 inhibitor activity against *Mycobacterium tuberculosis*. Front. Microbiol., 18 September 2020. https://doi.org/10.3389/fmicb.2020.553962
52. Lee A, Xie YL, Barry CE, Chen RY. 2020. Current and future treatments for tuberculosis. BMJ:m216. doi: 10.1136/bmj.m216. PMID: 32122882
53. Hernandez-Pando R. 2004. Persistence of DNA from *Mycobacterium tuberculosis* in superficially normal lung tissue during latent infection. Lancet 356:2133-2137. DOI: 10.1016/s0140-6736(00)03493-0
54. Mitchison DA. 2004. The search for new sterilizing anti-tuberculosis drugs. Frontiers in Bioscience 9:1059-1072. Dx.doi.org/10.2741/1293.

824 **Tables.**

825 **TABLE 1**: FNDR-20081: combination MIC with SoC 1st line, 2nd line and the new drugs in pipeline

Sl.no	2 drug combination		FIC index	Outcome
Invitro combination studies with First line drugs				
1	FNDR-20081	Isoniazid	1.29	Additive
2	FNDR-20081	Rifampicin	1.94	Indifference
3	FNDR-20081	Ethambutol	0.54	Synergy
Invitro combination studies with Second line drugs				
1	FNDR-20081	Capreomycin	2.99	Indifference
2	FNDR-20081	Kanamycin	2.99	Indifference
3	FNDR-20081	Streptomycin	3.09	Indifference
4	FNDR-20081	D-Cycloserine	1.70	Indifference
5	FNDR-20081	Amikacin	3.07	Indifference
6	FNDR-20081	Clofazimine	0.46	Synergy
7	FNDR-20081	Moxifloxacin	2.58	Indifference
In-vitro combination studies with New TB drugs				
1	FNDR-20081	Bedaquiline	1.06	Additive
2	FNDR-20081	PA-824	1.16	Additive
3	FNDR-20081	Linezolid	1.07	Additive
4	FNDR-20081	SQ109	1.94	Indifference

826

827

828 **TABLE 2**: Serum/ Plasma protein binding.

MIC Mtb (µg/ml)	7H9	7H9+10%FCS	7H9+10%BSA
FNDR-20081	0.5-1	2	2
RIF	0.0125	0.05	0.025
INH	0.06	0.12	0.12

829

830

831

832 **TABLE 3**: FNDR-20081 activity: **a.** under Low pH (1.2 log_{10} cfu/mL), Nutrient starvation (0.7 log_{10}
833 cfu/mL), stationary phase (0.2 log_{10} cfu/mL), **b**. Kill against replicating *vs.* non-replicating Mtb

a.

Conc. µg/ml	Emax (Log_{10} cfu reduction)					
	LpH		NSM		STA	
	20081	PZA	20081	RIF	20081	RIF
1	0.53	0.26	0.12	-0.06	-0.32	1.77
4	0.61	0.28	0.27	2.46	-0.16	2.25
16	0.75	0.55	0.51	2.95	-0.04	2.61
64	0.95	1.60	0.57	3.31	0.10	2.62
256	1.18	1.68	0.69	nd	0.18	nd

834 b.

Condition	Emax (Log_{10} cfu reduction)			
	Day	20081-256	RIF-64	PZA-256
REP-KK	D-14	2.1	nd	nd
LpH	D-21	1.2	nd	1.7
NSM	D-21	0.7	3.3	nd
STA	D-21	0.2	2.6	nd

835

836 **TABLE 4.** FNDR-20081: Activity against Mtb growing under a variety of nutritional sources

837

FNDR	1-week MIC 7H9/glucose/ casitone/Tx	2-week MIC 7H9/glucose/ casitone/Tx	1-week MIC 7H9/glucose/ BSA/Tx	2-week MIC 7H9/glucose/ BSA/Tx	1-week MIC 7H9/DPPC/ casitone/Tx	2-week MIC 7H9/DPPC/ casitone/Tx	1-week MIC 7H9/DPPC/ cholesterol/ BSA/Tx	2-week MIC 7H9/DPPC/ cholesterol/ BSA/Tx	Likely mycolyl-arabinogalactan biosynthetic inhibitor?
	ug/mL	ug/mL	ug/mL	ug/mL	ug/mL	ug/mL	ug/mL	ug/mL	
20081	6.1	12.2	12.2	18.06	9.27	9.27	12.2	18.06	No

838 **TABLE 5.** FNDR-20081: Activity against ESKAPE pathogens: *Enterococcus faecium* [VRE],
839 *Staphylococcus aureus* [MRSA], *Klebsiella pneumoniae* [sensitive], *Acinetobacter baumannii*
840 [sensitive], *Pseudomonas aeruginosa* [sensitive], *Enterobacter aerogenes* [sensitive]

MICROBIOLOGY	MIC (µg/ml)					
Compound No.	*Enterococcus faecium*	*Staphylococcus aureus*	*Klebsiella pneumoniae*	*Acinetobacter baumannii*	*Pseudomonas aeruginosa*	*Enterobacter aerogenes*
Strains details	Vancomycin-R	Methicillin-R	Drug-sensitive	Drug-sensitive	Drug-sensitive	Drug-sensitive
FNDR-20081	>32	>32	>32	>32	>32	>32

841 **Figure Legends**

842 **Figure 1.** Structure of FNDR-20081. Oxadiazole-piperazine-quinoline in tandem (4-{4-[5-(4-
843 Isopropyl-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-piperazin-1-yl}-7-pyridin-3-yl-quinoline). Mtb MIC
844 0.5µg/ml (1.02µM).

845 **Figure 2.** MIC of FNDR-20081 against 61 Mtb strains of different resistance patterns [Blue bar=WT
846 (1) Mtb strain, red bars=XDR(5), yellow bars=MDR(33), purple bars=SDR (15), and green bars=drug
847 sensitive (8) Mtb strains] grouped under two categories: low MIC range ($\leq$4µg/mL) and high MIC range
848 (up to 16µg/mL). Total $\geq$92% strains were sensitive to FNDR-20081. n= number of isolates under
849 respective low MIC or high MIC categories.

850 **Figure 3.** Killing kinetics of FNDR-20081. Residual $\log_{10}$ cfu/ml of Mtb post exposure to different
851 concentrations of FNDR-20081 tested from 0.015 to 256 µg/ml, enumerated on day-0, day-3, day-7, and
852 day-14. Time and concentration dependent (AUC) killing kinetics were demonstrated. FNDR-20081
853 showed an E_{max} of **2.1** $\log_{10}$ cfu/mL.

854 **Figure 4.** Efficacy of FNDR-20081 tested at different concentrations (0.03, 0.125, 0.5, 2 and 8 µg/ml)
855 against intracellular Mtb in THP-1 macrophages on day-0, day-3, day-5, and day-7. Emax=1.5 $\log_{10}$
856 cfu/mL

857 **Figure 5.** Activity of FNDR-20081 against DprE1 target over-expression in *M. bovis* BCG. A. Over-
858 expression of DprE1 conferred a greater than 16-fold increase in resistance to BTZ043 (assay control),
859 B. But no resistance to FNDR-20081.

860 **Figure 6.** Cross-resistance of FNDR-20081 spontaneous mutants to clotrimazole (CLT). MIC of the
861 mutants generated to FNDR-20081 was examined against CLT and FNDR-20081. Live bacteria were
862 identified by measuring fluorescence after resazurin addition (fluorescence of 100000 *vs*. 1000).

863 **Figure 7.** Drug metabolism and Pharmacokinetics (PK) of FNDR-20081. A. Drug metabolism. B.
864 Tabulated PK parameters at 30 and 300 mg/kg bw. C. Single dose *in-vivo* PK at two different doses.
865 Abbreviations used: MLM= Mouse Liver Microsomes, HLM= Human Liver Microsomes, MRT= Mean
866 Retention time.

867 **Figure 8.** Pharmacokinetics of FNDR-20081 in infected mice. A. Tabulated PK parameters. B. PK
868 profiles of 30 and 100 mg/kg doses.

869 **Figure 9.** *In-vivo* efficacy of FNDR-20081 at 10, 30 and 100mg/kg bw in chronic Mtb infection model
870 in BALB/c mice. Dose of 100mg/kg bw demonstrated significant ($P<0.05$) 0.56 log_{10} CFU/lung
871 reduction *vs.* untreated control.

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

Figures:



***FIG 1**: FNDR-20081.Oxadiazole--piperazine-quinoline in tandem (4-{4-[5-(4-Isopropyl-phenyl)-[1,2,4] oxadiazol-3-ylmethyl]-piperazin-1-yl}-7-pyridin-3-yl-quinoline). Mtb MIC 0.5µg/ml (1.02µM).*



***FIG 2.** Total 61 Mtb strains from different resistance patterns [XDR (5), MDR (33), SDR (15), drug sensitive (8)] grouped under into two categories: Low MIC range (≤4µg/mL) and High MIC range (up to 16µg/mL). Total ≥92% strains were sensitive to FNDR-20081.*

898



KK Emax	D0	D3	D7	D14
20081	0.0	0.7	1.2	2.1

899

900 ***FIG 3.*** *Killing kinetics:* FNDR-20081 exhibited time and concentration dependent (AUC) killing

901 kinetics, FNDR-20081 is a bactericidal compound, E_{max} = **2.1** log_{10} cfu/mL

902



903

904 ***FIG 4.*** *Intracellular efficacy Emax=1.5 log_{10} cfu/mL*

905

906



907 ***FIG 5.*** *Over-expression studies of DprE1 in M. bovis BCG. Over-expression of DprE1 confers a*

908 *greater than 16-fold increase in resistance to BTZ043, but no resistance to FNDR-20081.*

909

910



911

912 ***FIG 6.*** *Cross-resistance of FNDR-20081 spontaneous mutants to clotrimazole. The MIC of the mutants*

913 *generated to FNDR-20081 was examined in liquid culture, for clotrimazole and FNDR-20081, using a*

914 *2-fold serially diluted range of drugs in a 96 well plate. Live bacteria were identified by measuring*

915 *fluorescence after resazurin addition (fluorescence of 100,000 c.f. 1000).*

916

917 a.

Parameter		FNDR-20081
Liver microsomal stability (%)	MLM	**1.22**
	HLM	**40.1**
CYP 3A4 inhibition	IC_{50} (µM)	**>25**
HepG2 cell toxicity (%)	100 µM	**38.7**

918
919
920
921
922
923



924 b.

925
926
927
928
929
930
931
932 c.

Parameters	30 mg/kg, po	300 mg/kg po
C_{max} (µg/mL)	7.4	13.8
T_{max} (h)	0.5	1
AUC_{last} (h*µg/mL)	11.9	85.3
AUC_{inf} (h*µg/mL)	11.9	103.8
AUC_{extrap}(%)	0.59	17.78
MRT_{last} (h)	1.38	6.64

933

934 ***FIG 7***. *Pharmacokinetics of FNDR-20081. Tabulated and plotted Single dose in-vivo pharmacokinetics*
935 *at two different doses.*

936

937 a.

PK parameters of FNDR-20081 in infected animals (Day-26, repeat dosing)		
Parameters	**30**mg/kg	**100**mg/kg
C_{max} (µg/mL)	3.2	14.2
AUC_{last} (h*µg/mL)	8.3	69.5
MRT_{last} (h)	4.7	7.7
***In-vivo* efficacy (*Chronic Model*)**	**-0.2**	**0.6**

938
939
940
941
942
943
944



945 b.

946

947 ***FIG 8.*** *Pharmacokinetics of FNDR-20081 in infected mice.* ***a****: Tabulated values.* ***b****: Plotted day-26 in-*
948 *vivo pharmacokinetics in infected animals at two different doses.*

949



950

951 ***FIG 9.*** *In-vivo efficacy of FNDR-20081 in BALB/c mice demonstrated significant (P<0.05) 0.56* log_{10}
952 *CFU/lung reduction.*

953

954 Supplementary Table S1:

Table S1 FNDR-20081 spontaneous resistance mutants in BCG. WGS data and mutation mapping.

CHROM	POS	TYPE	REF	ALT	EVIDENCE	FTY	STRA	NT_POS	AA_POS	EFFECT	LOCUS_TAG	GENE	PRODUCT	FNDR22	FNDR23	FNDR27	number_sa	ples_with_variant
NC_008769	1E+06	complex	CG	GC	GC:8 CG:0										GC:8 CG:0		1	
NC_008769	2E+06	snp	G	C	C:5 G:0	CDS	-	1926/2223	642/740	synonymous_variant c.1926C>G p.Gly642Gly	BCG_1513c		PE family protein	C:5 G:0			1	
NC_008769	2E+06	complex	CG	CCGGC	CCGGC:7 CG:	CDS	-	666/2690	222/895	disruptive_inframe_insertion & synonymous_variant c.666delCinsGCCG p.Thr222_Val223insPro	BCG_1799c	Rv1759c	hypothetical protein	CCGGC:7 CG:	CCGGC:7 CG:	CCGGC:6 CG:	3	non essential gene by Himar1-based transposon mutagenesis in H37Rv strain (see Sassetti et al., 2003) deleted in some clinical isolates
NC_008769	3E+06	snp	T	A	A:36 T:0	CDS	-	531/3414	177/1137	synonymous_variant c.531A>T p.Thr177Thr	BCG_2507c		LuxR family transcriptional regulator	A:36 T:0	A:42 T:0	A:33 T:0	3	
NC_008769	3E+06	ins	TTA	TATA	TATA:56 TTA	CDS	+	75/1743	25/580	frameshift_variant c.74_75insA p.Phe25fs	BCG_2963		long-chain-fatty-acid--AMP ligase FadD28		TATA:56 TTA:0		1	
NC_008769	4E+06	snp	C	T	T:26 C:0	CDS	-	102/1158	34/385	synonymous_variant c.102G>A p.Pro34Pro	BCG_3265c		cation:proton antiporter	T:26 C:0	T:46 C:0	T:31 C:0	3	
NC_008769	4E+06	ins	GGC	GGCCGC	GGCCGC:17 (	CDS	-	1296/1419	432/472	conservative_inframe_insertion c.1296_1297insGCG p.Ala432dup	BCG_3499c	Rv3433c	bifunctional ADP-dependent NAD(P)H-hydrate dehydratase/NAD(P)H-hydrate epimerase	GGCCGC:17 (	GGCCGC:13 GGC:0		2	non essential gene by Himar1-based transposon mutagenesis in H37Rv strain (see Sassetti et al., 2003) disruption causes growth advantage in vitro
NC_008769	4E+06	ins	GGC	GGTCGC	GGTCGC:18 (	CDS	+	783/786	261/261	disruptive_inframe_insertion c.782_783insTCG p.Gly261_Ter262insArg	BCG_3517	Rv3451	cutinase family protein	GGTCGC:18 (	GGTCGC:21 (	GGTCGC:9 G(	3	KO is more resiliant to stress
NC_008769	4E+06	snp	A	G	G:5 A:0	CDS	+	1795/4119	599/1372	missense_variant c.1795A>G p.Asn599Asp	BCG_3571		PE family protein	G:5 A:0	G:7 A:0	G:10 A:0	3	
NC_008769	4E+06	snp	C	T	T:11 C:0	CDS	+	2115/4119	705/1372	synonymous_variant c.2115C>T p.Gly705Gly	BCG_3571		PE family protein	T:11 C:0	T:10 C:0	T:15 C:0	3	
NC_008769	4E+06	snp	A	G	G:5 A:0	CDS	+	1792/3228	598/1075	missense_variant c.1792A>G p.Thr598Ala	BCG_3577		PE family protein	G:5 A:0		G:6 A:0	2	
NC_008769	4E+06	snp	C	A	A:40 C:3	CDS	+	564/960	188/319	missense_variant c.564C>A p.Asp188Glu	BCG_3742	Rv3683	metallophosphoesterase	A:40 C:3	A:41 C:0	A:27 C:0	3	non essential gene by Himar1-based transposon mutagenesis in H37Rv strain (see Sassetti et al., 2003)
NC_008769	4E+06	snp	C	G	G:34 C:3	CDS	-	1128/1530	376/509	missense_variant c.1128G>C p.Leu376Phe	BCG_3755c	glpK	glycerol kinase GlpK	G:34 C:3	G:35 C:0	G:23 C:0	3	
NC_008769	705623	complex	GTGG	ATGC	ATGC:7 GTG(	CDS	-	1176/3912	391/1303	synonymous_variant c.1173_1176delCCACinsGCAT p.393	BCG_0623c		PE family protein	ATGC:7 GTGG:0			1	